Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML. Cancer cell Thomas, R., Majeti, R. 2019; 35 (3): 337–39
Abstract
A report in this issue of Cancer Cell identifies the RNA-binding protein RBM39 as a potential target in spliceosome mutant AML that can be targeted by existing sulfonamide drugs. These results support a proposed clinical trial in patients with myeloid malignancies bearing spliceosome mutations relapsed or refractory to standard therapy.
View details for PubMedID 30889374